Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis.

Hussain Sohail RangwalaHareer FatimaMirha AliSyed Taha AhmedBurhanuddin Sohail RangwalaSyed Raza Abbas

Published in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2023)

Our study suggests that Mavacamten may have therapeutic benefits for HCM patients, as indicated by its positive impact on certain endpoints. Further research with larger samples, longer follow-up, and comprehensive analysis is needed to understand Mavacamten's safety and efficacy in HCM patients.

Keyphrases

hypertrophic cardiomyopathy
end stage renal disease
newly diagnosed
ejection fraction
randomized controlled trial
prognostic factors
peritoneal dialysis
left ventricular
heart failure
clinical trial
patient reported
atrial fibrillation